Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

被引：9
|
作者：
Weitz, Ilene Ceil [1 ]
机构：
[1] Keck USC Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90089 USA
来源：
JOURNAL OF BLOOD MEDICINE | 2023年 / 14卷
关键词：
PNH; complement inhibition; extravascular hemolysis; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ECULIZUMAB; HEMOLYSIS;
D O I：
10.2147/JBM.S362220
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.
引用
收藏
页码：239 / 245
页数：7
相关论文
共 50 条
  • [41] A NOVEL APPROACH TO CELL-TARGETED COMPLEMENT INHIBITION IN PNH: THE HUMAN COMPLEMENT RECEPTOR 2/FACTOR H FUSION PROTEIN TT30 PREVENTS BOTH HEMOLYSIS AND UPSTREAM C3-OPSONIZATION OF PNH ERYTHROCYTES
    Pascariello, C.
    Selleri, C.
    Del Vecchio, L.
    Sica, M.
    Horvath, C.
    Holers, M.
    Luzzatto, L.
    Risitano, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 245 - 245
  • [42] EXAMINATION OF COMPLEMENT PROTEINS ON MEMBRANES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND PNH-LIKE RED-CELLS
    BURAPAKULSOLSRI, N
    YUTHAVONG, Y
    WILAIRAT, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1979, 41 (03) : 393 - 398
  • [43] Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
    Imre Bodó
    Ismail Amine
    Ana Boban
    Horia Bumbea
    Alexander Kulagin
    Elena Lukina
    Agnieszka Piekarska
    Irena Preloznik Zupan
    Juraj Sokol
    Jerzy Windyga
    Jaroslav Cermak
    Advances in Therapy, 2023, 40 : 2752 - 2772
  • [44] Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
    Bodo, Imre
    Amine, Ismail
    Boban, Ana
    Bumbea, Horia
    Kulagin, Alexander
    Lukina, Elena
    Piekarska, Agnieszka
    Zupan, Irena Preloznik
    Sokol, Juraj
    Windyga, Jerzy
    Cermak, Jaroslav
    ADVANCES IN THERAPY, 2023, 40 (06) : 2752 - 2772
  • [45] Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
    Wong, Raymond Siu Ming
    Navarro-Cabrera, Juan Ramon
    Comia, Narcisa Sonia
    Goh, Yeow Tee
    Idrobo, Henry
    Kongkabpan, Daolada
    Gomez-Almaguer, David
    Al-Adhami, Mohammed
    Ajayi, Temitayo
    Alvarenga, Paulo
    Savage, Jessica
    Deschatelets, Pascal
    Francois, Cedric
    Grossi, Federico
    Dumagay, Teresita
    BLOOD ADVANCES, 2023, 7 (11) : 2468 - 2478
  • [46] A complementary new drug for PNH
    Brodsky, Robert A.
    BLOOD, 2020, 135 (12) : 884 - 885
  • [47] A First Report from the COMPLETE Study on the Real-World Effectiveness of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    de Latour, Regis Peffault
    Trikha, Roochi
    Gonzalez, Carmen Gonzalez
    Nolte, Matthias
    Malmstrom, Hakan
    Lethagen, Stefan
    BLOOD, 2024, 144 : 5669 - 5670
  • [48] A REAL-WORLD ANALYSIS OF TREATMENT ADHERENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) RECEIVING PEGCETACOPLAN
    Wilson, Koo
    Rich, Carly
    Hakimi, Zalmai
    Horneff, Regina
    Fishman, Jesse
    Mellor, Jennifer
    Earl, Lucy
    Taylor, Yasmin
    Simons, Alice
    BONE MARROW TRANSPLANTATION, 2024, 59 : 190 - 191
  • [49] Targeted complement regulators protect PNH erythrocytes from acid hemolysis
    Spitzer, Dirk
    Atkinson, John P.
    MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 243 - 244
  • [50] PNH and complement gene variants (vol 141, pg 1780, 2023)
    Risitano, A. M.
    BLOOD, 2023, 142 (25) : 2221 - 2221
12345